Objectives: Recently, there have been reports regarding the atrophy of various organs caused by molecular targeted drugs. We investigated morphological and clinical changes in the liver and pancreas caused by treatment with bevacizumab.

Methods: We investigated 30 patients with colorectal cancer who received bevacizumab-containing chemotherapy (study group) and 11 patients with colorectal cancer who received chemotherapy without bevacizumab (control group) from 2010 to 2014. We obtained computed tomography data of the liver and pancreas and performed three-dimensional image analysis and volumetry. Laboratory data before and after chemotherapy were analyzed.

Results: There was no significant difference in liver volume before and after bevacizumab-containing chemotherapy, but the pancreatic volume was found to be significantly reduced after bevacizumab-containing chemotherapy (57.9 ± 16 mL versus 47.4 ± 15.3 mL; p = .005). The liver and pancreatic volume did not change statistically in the control group. With regard to complete blood cell counts and laboratory data, no significant differences were observed in the leukocyte count and hemoglobin, hemoglobin A1c, triglyceride, albumin, and C-reactive protein levels. In contrast, there was a significant decrease in the platelet count, total cholesterol level and a significant increase in the amylase level. A chemotherapy regimen that included bevacizumab reduced pancreatic volume and significantly altered the morphology of the pancreas.

Conclusions: Although bevacizumab caused atrophy of the pancreas and reduced pancreatic volume, pancreatic endocrine function showed no change. Future studies should investigate the survival rate and functional changes caused by bevacizumab treatment.

目的：最近，有关分子靶向药物引起的各种器官萎缩的报道。我们调查了贝伐单抗治疗引起的肝脏和胰腺的形态和临床变化。

方法： 2010年至2014年，我们调查了30例接受贝伐单抗化疗的结直肠癌患者（研究组）和11例未使用贝伐单抗化疗的结直肠癌患者（对照组）。进行了三维图像分析和体积测量。分析了化疗前后的实验室数据。

结果：含贝伐单抗的化疗前后肝体积无明显差异，但含贝伐单抗的化疗后胰脏体积明显减少（57.9±16 mL对47.4±15.3 mL；p = .005）。对照组的肝脏和胰腺体积没有统计学变化。关于全血细胞计数和实验室数据，在白细胞计数和血红蛋白，血红蛋白A1c，甘油三酸酯，白蛋白和C反应蛋白水平上未观察到显着差异。相反，血小板计数，总胆固醇水平显着降低，而淀粉酶水平显着提高。包含贝伐单抗的化疗方案可减少胰腺体积，并显着改变胰腺的形态。

结论：尽管贝伐单抗引起胰腺萎缩并减少胰腺体积，但胰腺内分泌功能未见改变。未来的研究应调查贝伐单抗治疗引起的存活率和功能改变。